TD Cowen analyst Marc Frahm has maintained their bullish stance on STTK stock, giving a Buy rating on March 17.
Marc Frahm has given his Buy rating due to a combination of factors that highlight the potential of Shattuck Labs’ lead asset, SL-325. The preclinical data presented at ECCO 2025 demonstrated that SL-325, an anti-DR3 antagonist monoclonal antibody, has a favorable safety profile and effectively engages its target receptor. This is significant as it suggests SL-325 could offer superior control of gut inflammation in inflammatory bowel disease (IBD) compared to existing treatments.
Moreover, the absence of adverse effects in non-human primate studies across various dosages further supports the drug’s safety and efficacy. With an Investigational New Drug (IND) application expected in the third quarter of 2025 and initial clinical data anticipated in 2026, Shattuck Labs is positioned for potential growth. These promising developments underpin Frahm’s confidence in the company’s future prospects, justifying the Buy rating.
Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Blueprint Medicines, and Scholar Rock Holding. According to TipRanks, Frahm has an average return of 1.1% and a 34.04% success rate on recommended stocks.
In another report released on March 17, Leerink Partners also initiated coverage with a Buy rating on the stock with a $4.00 price target.